{"transactions":[{"id":701483,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":28031,"kind":"person","name":"Pacala Mark L","position":1,"cik":"0001321250","reported_name":"Pacala Mark L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-29T22:53:11.000Z","date":"2026-07-27","kind":"grant","planned":false,"acquired":true,"shares":30120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date."}],"balance_after":286881,"source":{"system":"sec-edgar","filing":"0001079973-26-000989","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000107997326000989/ownership.xml","form_type":"4"}},{"id":990198,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":28031,"kind":"person","name":"Pacala Mark L","position":1,"cik":"0001321250","reported_name":"Pacala Mark L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-24T22:21:04.000Z","date":"2025-11-20","kind":"grant","planned":false,"acquired":true,"shares":35494,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock units that were fully vested upon grant."}],"balance_after":256761,"source":{"system":"sec-edgar","filing":"0001553350-25-000144","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000155335025000144/ownership.xml","form_type":"4"}},{"id":990197,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":28031,"kind":"person","name":"Pacala Mark L","position":1,"cik":"0001321250","reported_name":"Pacala Mark L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-24T22:21:04.000Z","date":"2025-11-20","kind":"grant","planned":false,"acquired":true,"shares":46296,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest in full on Issuer's 2026 annual stockholder meeting date, subject to continued service with the Issuer through such vesting date."}],"balance_after":221267,"source":{"system":"sec-edgar","filing":"0001553350-25-000144","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000155335025000144/ownership.xml","form_type":"4"}},{"id":992572,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":28031,"kind":"person","name":"Pacala Mark L","position":1,"cik":"0001321250","reported_name":"Pacala Mark L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-20T21:55:03.000Z","date":"2025-11-18","kind":"sale","planned":false,"acquired":false,"shares":46630,"price":4,"value":186520.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents sale of Common Stock acquired from previously vested RSU awards."}],"balance_after":174971,"source":{"system":"sec-edgar","filing":"0001079973-25-001813","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000107997325001813/ownership.xml","form_type":"4"}},{"id":992571,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":28031,"kind":"person","name":"Pacala Mark L","position":1,"cik":"0001321250","reported_name":"Pacala Mark L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-20T21:55:03.000Z","date":"2025-11-18","kind":"sale","planned":false,"acquired":false,"shares":1210,"price":4,"value":4840.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents sale of Common Stock acquired from previously vested RSU awards."}],"balance_after":221601,"source":{"system":"sec-edgar","filing":"0001079973-25-001813","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000107997325001813/ownership.xml","form_type":"4"}},{"id":992570,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":28031,"kind":"person","name":"Pacala Mark L","position":1,"cik":"0001321250","reported_name":"Pacala Mark L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-20T21:55:03.000Z","date":"2025-11-18","kind":"sale","planned":false,"acquired":false,"shares":2160,"price":4,"value":8640.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents sale of Common Stock acquired from previously vested RSU awards."}],"balance_after":222811,"source":{"system":"sec-edgar","filing":"0001079973-25-001813","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000107997325001813/ownership.xml","form_type":"4"}},{"id":1188876,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":28031,"kind":"person","name":"Pacala Mark L","position":1,"cik":"0001321250","reported_name":"Pacala Mark L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Warrant","published_at":"2025-03-28T21:41:49.000Z","date":"2025-03-26","kind":"purchase","planned":false,"acquired":true,"shares":42281,"price":0.125,"value":5285.125,"ownership":{"direct":false,"nature":"By LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the \"Private Placement\"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued Private Placement units consisting of two shares of the Company's common stock (\"Common Stock\") and a common warrant (\"Common Warrant\") to purchase one share of Common Stock (the \"Private Placement Unit\")."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the \"Private Placement\"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued Private Placement units consisting of two shares of the Company's common stock (\"Common Stock\") and a common warrant (\"Common Warrant\") to purchase one share of Common Stock (the \"Private Placement Unit\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The holder may not exercise any portion of a Common Warrant to the extent that the holder would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately prior to or after giving effect to such exercise, as such percentage ownership is determined in accordance with Section 13(d) under the Securities Exchange Act of 1934, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities were purchased by Pacala Enterprises, LLC, an entity controlled by the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein."}],"balance_after":42281,"derivative":{"exercise_price":1.198,"exercise_date":"2025-03-26","expiration_date":"2030-03-26","underlying":"Common Stock","underlying_shares":42281},"source":{"system":"sec-edgar","filing":"0001079973-25-000525","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000107997325000525/ownership.xml","form_type":"4"}},{"id":1188875,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":28031,"kind":"person","name":"Pacala Mark L","position":1,"cik":"0001321250","reported_name":"Pacala Mark L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-28T21:41:49.000Z","date":"2025-03-26","kind":"purchase","planned":false,"acquired":true,"shares":90562,"price":1.0417,"value":94338.4354,"ownership":{"direct":false,"nature":"By LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the \"Private Placement\"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued Private Placement units consisting of two shares of the Company's common stock (\"Common Stock\") and a common warrant (\"Common Warrant\") to purchase one share of Common Stock (the \"Private Placement Unit\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities were purchased by Pacala Enterprises, LLC, an entity controlled by the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein."}],"balance_after":224971,"source":{"system":"sec-edgar","filing":"0001079973-25-000525","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000107997325000525/ownership.xml","form_type":"4"}},{"id":1352804,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":28031,"kind":"person","name":"Pacala Mark L","position":1,"cik":"0001321250","reported_name":"Pacala Mark L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-11-25T21:32:09.000Z","date":"2024-11-22","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest in full on TOI, Inc.'s 2025 annual shareholder meeting date, subject to continued service with the Company through such vesting date."}],"balance_after":134409,"source":{"system":"sec-edgar","filing":"0001799191-24-000059","document":"wk-form4_1732570323.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919124000059/wk-form4_1732570323.xml","form_type":"4"}},{"id":1361861,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":28031,"kind":"person","name":"Pacala Mark L","position":1,"cik":"0001321250","reported_name":"Pacala Mark L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-11-18T23:52:13.000Z","date":"2024-11-12","kind":"other","planned":false,"acquired":false,"shares":30372,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects the forfeiture of restricted earn-out shares that were unvested due to failure to meet earnout targets of the Issuer's stock price of $15.00 per share for 20 days within any 30 consecutive trading days for the three-year period following November 12, 2021, the date of the closing of the Business Combination, subject to continued employment at such time."}],"balance_after":84409,"source":{"system":"sec-edgar","filing":"0001799191-24-000035","document":"wk-form4_1731973928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919124000035/wk-form4_1731973928.xml","form_type":"4"}},{"id":1361860,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":28031,"kind":"person","name":"Pacala Mark L","position":1,"cik":"0001321250","reported_name":"Pacala Mark L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-11-18T23:52:13.000Z","date":"2024-11-12","kind":"other","planned":false,"acquired":false,"shares":20248,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the forfeiture of restricted earn-out shares that were unvested due to failure to meet earnout targets of the Issuer's stock price of $12.50 per share for 20 days within any 30 consecutive trading days for the three-year period following November 12, 2021, the date of the closing of the Business Combination, subject to continued employment at such time."}],"balance_after":114781,"source":{"system":"sec-edgar","filing":"0001799191-24-000035","document":"wk-form4_1731973928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919124000035/wk-form4_1731973928.xml","form_type":"4"}},{"id":1698707,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":28031,"kind":"person","name":"Pacala Mark L","position":1,"cik":"0001321250","reported_name":"Pacala Mark L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-12-28T21:09:47.000Z","date":"2023-12-26","kind":"grant","planned":false,"acquired":true,"shares":46630,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units that vest in full on TOI, Inc. 2024 annual shareholder meeting date, subject to continued service with the Company through such vesting date."}],"balance_after":135029,"source":{"system":"sec-edgar","filing":"0001628280-23-042795","document":"wk-form4_1703797778.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828023042795/wk-form4_1703797778.xml","form_type":"4"}},{"id":1943159,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":28031,"kind":"person","name":"Pacala Mark L","position":1,"cik":"0001321250","reported_name":"Pacala Mark L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-03-22T00:46:14.000Z","date":"2023-03-17","kind":"grant","planned":false,"acquired":true,"shares":6562,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest in full on March 16, 2024, subject to continued service with the Company through such vesting date."}],"balance_after":88399,"source":{"system":"sec-edgar","filing":"0001628280-23-008827","document":"wf-form4_167944596405529.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828023008827/wf-form4_167944596405529.xml","form_type":"4"}},{"id":2108730,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":28031,"kind":"person","name":"Pacala Mark L","position":1,"cik":"0001321250","reported_name":"Pacala Mark L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-21T22:34:18.000Z","date":"2022-11-17","kind":"grant","acquired":true,"shares":29057,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units that vest in full on May 17, 2023, subject to continued service with the Company through such vesting date."}],"balance_after":81837,"source":{"system":"sec-edgar","filing":"0001799191-22-000039","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919122000039/edgardoc.xml","form_type":"4"}},{"id":2108729,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":28031,"kind":"person","name":"Pacala Mark L","position":1,"cik":"0001321250","reported_name":"Pacala Mark L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-21T22:34:18.000Z","date":"2022-11-17","kind":"grant","acquired":true,"shares":2160,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":52780,"source":{"system":"sec-edgar","filing":"0001799191-22-000039","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919122000039/edgardoc.xml","form_type":"4"}}]}